1.Ventracor's product is approved for sale in Europe and...

1.Ventracor's product is approved for sale in Europe and Australia, and with high barriers for further competitors entering the market, investors should be comforted.
AFR Smart Investor Magazine 25/09/07

# VCR is 2 long years ahead of HTW.

2.We were very impressed by this device. We thought that it had a low complication rate, it's very small.
Dr Deborah Meyers, Prince Charles Hospital 12/09/07

# It is very small...small enough to be used in a child.

3.Ventracor is moving to an important inflexion point for the commercialisation of its technology. A profitable market currently exists for LVADs and there is a positive swing in events that is likely to see a wider adoption of LVADs into the far larger market of destination therapy, which is estimated to be in excess of 25,000 implants a year.
BioShares investment newsletter 22/06/07

# Thoratec, the no.1 player in the US has implanted over 11,000 devices to date. It has a market cap of over $1billion.